Ralliant (NYSE:RAL) Issues Q3 2026 Earnings Guidance

Ralliant (NYSE:RAL) updated its third quarter 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 0.720-0.780 for the period, compared to the consensus estimate of 0.680. The company issued revenue guidance of $570.0 million-$590.0 million, compared to the consensus revenue estimate of $556.4 million. Ralliant also updated its FY 2026 guidance to 2.760-2.900 EPS.

Ralliant Price Performance

Shares of NYSE RAL opened at $66.85 on Thursday. The company has a quick ratio of 1.05, a current ratio of 1.61 and a debt-to-equity ratio of 0.73. Ralliant has a fifty-two week low of $37.27 and a fifty-two week high of $75.41. The business has a 50 day moving average price of $66.98 and a two-hundred day moving average price of $54.16. The firm has a market cap of $7.48 billion and a PE ratio of -6.11.

Ralliant (NYSE:RAL) last announced its earnings results on Thursday, July 30th. The company reported $0.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.63 by $0.05. The company had revenue of $567.80 million for the quarter. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. Sell-side analysts expect that Ralliant will post 2.64 earnings per share for the current fiscal year.

Ralliant Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 23rd. Investors of record on Monday, June 8th were paid a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date was Monday, June 8th. Ralliant’s dividend payout ratio (DPR) is -1.83%.

Analyst Upgrades and Downgrades

RAL has been the subject of several research analyst reports. Barclays boosted their price objective on Ralliant from $52.00 to $67.00 and gave the company an “overweight” rating in a report on Wednesday, May 13th. Wall Street Zen lowered Ralliant from a “buy” rating to a “hold” rating in a research report on Sunday. Zacks Research upgraded Ralliant from a “hold” rating to a “strong-buy” rating in a report on Tuesday, June 30th. Morgan Stanley upped their price target on Ralliant from $68.00 to $85.00 and gave the company an “overweight” rating in a research report on Tuesday, June 23rd. Finally, Evercore began coverage on Ralliant in a research note on Tuesday, June 9th. They set an “outperform” rating and a $80.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $73.00.

Institutional Trading of Ralliant

Institutional investors and hedge funds have recently made changes to their positions in the stock. Palisade Asset Management LLC bought a new stake in shares of Ralliant in the 3rd quarter worth approximately $26,000. BOKF NA acquired a new position in Ralliant during the 3rd quarter valued at approximately $29,000. Wilmington Savings Fund Society FSB bought a new position in Ralliant during the 3rd quarter worth $30,000. EverSource Wealth Advisors LLC bought a new position in Ralliant during the 2nd quarter worth $39,000. Finally, NewEdge Advisors LLC bought a new position in Ralliant during the 2nd quarter worth $43,000.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.